RxDoctor Payments Data

Markham Nightengale, MD

Gastroenterology · Tulsa, OKNPI 1144215971

Payments from drug & device makers

$1,488in general payments, 2019–2025

Across 91 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$644
  • Olympus America Inc.$188
  • Boston Scientific$117
  • Johnson & Johnson$104
  • Pfizer$82
  • Lilly USA, LLC$79
  • plus $274 from 13 others

What the payments were for

  • Food & beverage$1,488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,488 in reported general payments places this provider in the 30th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$194,910
Medicare patients
613
Services billed
3,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$30,754
VemlidyTenofovir Alafenamide11$13,254
Omeprazole481$9,450
Mesalamine12$6,857
ClenpiqSod Picosulf/Mag Ox/Citric Ac38$6,447
Dexlansoprazole DrDexlansoprazole19$5,997
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag46$5,726
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C38$5,470
Mesalamine ErMesalamine20$4,640
Lansoprazole19$4,583
SutabSod Sulf/Pot Chloride/Mag Sulf19$3,091
Pantoprazole Sodium126$2,417
Ursodiol17$2,092
Colestipol Hcl18$1,214
Azathioprine23$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$644$30,75412 claims
GileadVemlidy$18$13,25411 claims
Braintree Laboratories, Inc.Suflave, Sutab$14$8,81765 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$32$5,47038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →